{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Acute Respiratory Distress Syndrome",
            "NStudiesAvail": 430108,
            "NStudiesFound": 56,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 56,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Amanda L. Olson, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 13, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Adverse Events determined by CTCAE version 4."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)"
                        ],
                        "NCTId": [
                              "NCT02804945"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [
                              "michael.matthay@ucsf.edu"
                        ],
                        "PointOfContactOrganization": [
                              "University of California San Francisco"
                        ],
                        "PointOfContactPhone": [
                              "415-353-1206"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Michael A. Matthay, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "February 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Any of the following occurring within 6 h of mesenchymal stem-cell infusion:\n\nAddition of a third vasopressor or an increase in vasopressor dose greater than or equal to the following:\nNorepinephrine: 10 \u03bcg per min\nPhenylephrine: 100 \u03bcg per min\nDopamine: 10 \u03bcg/kg per min\nEpinephrine: 0\u00b71 \u03bcg/kg per min\nHypoxaemia requiring an increase in the fraction of inspired oxygen of \u22650\u00b72 and increase in positive end-expiratory airway pressure level of 5 cm H2O or more to maintain transcutaneous oxygen saturations in the target range of 88-95%\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fi brillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24 h of mesenchymal stem-cell infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Pre-specified Infusion Associated Adverse Events"
                        ],
                        "NCTId": [
                              "NCT01775774"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Alfredo Hernandez-Ruiz, MSc"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation of efficacy of WJ-MSC defined by mortality at 28 days of application."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Intergroup mortality difference with treatment"
                        ],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Compare the adverse events between mesenchymal stem cell treatment and placebo groups"
                        ],
                        "NCTId": [
                              "NCT01902082"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Huimin Yi"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 1, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of prescribed adverse events or unprescribed events agreed by investigators and consultant .",
                              "All cause mortality. Cause of death, exact survival status (death/survival) and time (days) will also be recorded"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Infusion associated events",
                              "Mortality"
                        ],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the PaO2 / FiO2 ratio.",
                              "To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the heart rate per minute.",
                              "To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the respiratory rate per minute.",
                              "To describe the clinical changes secondary to IV administration of AMSCa, in patients with bilateral COVID-19 pneumonia complicated by severe SIRA, with the evaluation of the fever curve in degrees centigrade."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Functional Respiratory changes: PaO2 / FiO2 ratio",
                              "Clinical cardiac changes: Heart rate per minute",
                              "Clinical Respiratory Changes: Respiratory rate per minute",
                              "Changes in body temperature"
                        ],
                        "NCTId": [
                              "NCT04416139"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Fermin Labayen Beraza, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 15, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection"
                        ],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Amanda Olson"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 30, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of composite serious adverse events (Phase I)",
                              "Patients alive without grade 3, 4 infusional toxicity (Phase II)",
                              "Patients alive with grade 3 or 4 infusional toxicity (Phase II)",
                              "Patients not alive (Phase II)"
                        ],
                        "NCTId": [
                              "NCT04565665"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Abdol Hossein Shahverdi",
                              "Hossein Baharvand, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 6, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",
                              "Evaluation of Pneumonia Improvement"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events assessment",
                              "Blood oxygen saturation"
                        ],
                        "NCTId": [
                              "NCT04366063"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of adverse reaction",
                              "Time to Clinical improvement",
                              "28-day mortality"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of adverse reaction",
                              "TTCI",
                              "28-day mortality"
                        ],
                        "NCTId": [
                              "NCT04602104"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Mike Royal, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "All-cause mortality rate at Day 28"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "All-cause mortality rate at Day 28"
                        ],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Jesus Perez",
                              "Juan Parcero"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 15, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of patients with changes in percentage of resting Oxygen saturation (%O2)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Oxygen saturation"
                        ],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Antoine KIMMOUN, MD, PhD",
                              "S\u00e9bastien GIBOT, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 14, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint is the percentage of patients with a PaO2/FiO2 ratio > 200 at D10 of treatment with MSC-GW or placebo."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "PaO2 / FiO2 ratio"
                        ],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of Treatment-Emergent Adverse Events (TEAEs). Incidence of withdrawals due to AEs."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The incidence and frequency of adverse events related to administration of UMC119-06."
                        ],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 3, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary efficacy endpoint is overall 60-day mortality (due to any cause)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The primary efficacy endpoint is overall 60-day mortality (due to any cause)."
                        ],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluate incidences of Treatment-Emergent Adverse Events following EV-Pure\u2122 and WJ-Pure\u2122 administeration in patients exhibiting moderate to severe ARDS associated with COVID-19 compared to placebo. Presence of adverse events in less than 10% of the study population, as a measure of safety",
                              "Clinical data will be evaluated to determine if there were any significant changes in the COVID-19 symptoms in patients in the treated versus placebo groups. The following information will be collected to evaluate the effectiveness of the treatment at 4 weeks post- treatment:\n\nDischarged home on no supplemental oxygen\nDischarged home on supplemental oxygen\nContinued hospitalization on no oxygen\nContinued hospitalization on oxygen but not in ICU\nContinued hospitalization on oxygen in ICU (invasive and noninvasive ventilatory support)\nDeath"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To Assess the safety of EV-Pure\u2122 and WJ-Pure\u2122 administration in patients exhibiting moderate to severe ARDS associated with COVID-19, compared to placebo.",
                              "To assess the efficacy of EV-Pure\u2122 and WJ-Pure\u2122 compared to placebo, in patients with moderate to severe ARDS assoociated with COVID-19"
                        ],
                        "NCTId": [
                              "NCT05387278"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The incidence of serious adverse events.",
                              "Number to patients with All-Cause Mortality at 28 days"
                        ],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Ahmet AKYOL, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "Yes"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 28, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "It was aimed to observe the changes in C-reactive protein (CRP), after MSC administration at different times (groups 1,2,3).",
                              "It was aimed to observe the changes in procalcitonin after MSC administration at different times (groups 1,2,3).",
                              "It was aimed to observe the changes in white blood cell count after MSC administration at different times (groups 1,2,3).",
                              "It was aimed to observe the changes in respiratory support (such as high-flow nasal oxygen, mask with reservoir, and mechanical ventilation) after MSC administration at different times (groups 1,2,3).",
                              "It was aimed to observe the changes in arterial blood gas analysis after MSC administration in Groups I, II, III."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in acute phase reactants (C-reactive protein (CRP) after MSC administration in group I, II, III",
                              "Change in acute phase reactants (procalcitonin) after MSC administration in group I, II, III",
                              "Change in acute phase reactants ( white blood cell count) after MSC administration in group I, II, III",
                              "Changes in respiratory support after MSC administration in Groups I, II, III",
                              "Changes in arterial blood gas analysis (partial oxygen/fractionated oxygen (Pa/Fi) ratio) after MSC administration in Groups I, II, III"
                        ],
                        "NCTId": [
                              "NCT05240430"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Oscar Simonsson, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The incidence of pre-specified treatment related adverse events of interest (TRAEIs) occurring during the 10 days interval beginning with the start of the ATIMP infusion:\n\nNew ventricular tachycardia, ventricular fibrillation or asystole within 10 days after infusion\nNew cardiac arrhythmia requiring cardioversion within 10 days after infusion\nClinical scenario consistent with transfusion incompatibility or transfusion-related infection within 10 days after infusion\nThromboembolic events (e.g. Pulmonary embolism) within 10 days after infusion\nCardiac arrest or death within 10 days after infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The incidence of pre-specified treatment related adverse events of interest (TRAEIs)."
                        ],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Bing Liu, M.D.",
                              "Changqing Bai, M.D.",
                              "Huiying Liu, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be determined by the assessment of major adverse events defined as death, and the incidence of prespecified infusion-associated events and non-serious adverse events thought to be related to the MSC infusion."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety will be determined by the assessment of major adverse events"
                        ],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [
                              "Camillo Ricordi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "ricordi@miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "University of Miami"
                        ],
                        "PointOfContactPhone": [
                              "305-243-6913"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Camillo Ricordi"
                        ],
                        "PrimaryCompletionDate": [
                              "October 31, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety as defined by the number of pre-specified infusion associated adverse events as assessed by treating physician. Any of the following occurring within 6 h post each infusion:\n\nAn increase in vasopressor dose greater than or equal to the following:\n\nNorepinephrine: 10 \u03bcg/min\nPhenylephrine: 100 \u03bcg/min\nDopamine: 10 \u03bcg/kg/min\nEpinephrine: 10 \u03bcg/min\nIn patients receiving mechanical ventilation: worsening hypoxemia, as assessed by a requirement for an increase of PEEP by 5 cm H2O over baseline, or requirement to increase FiO2 of >20%.\nIn patients receiving high flow oxygen therapy: worsening hypoxemia, as indicated by requirement of intubation and mechanical ventilation.\nNew cardiac arrhythmia requiring cardioversion\nNew ventricular tachycardia, ventricular fibrillation, or asystole\nA clinical scenario consistent with transfusion incompatibility or transfusion-related infection\nCardiac arrest or death within 24h post infusion",
                              "The number of subjects experiencing serious adverse events by 31 days after the first infusion (corresponding to 28 days after the last infusion).",
                              "Safety will be reported as the percentage of participants experiencing serious adverse events through Day 90 as assessed by treating physician.",
                              "Total number of adverse events and serious adverse events as assessed by treating physician",
                              "Total number of adverse events plus serious adverse events categorized by severity.",
                              "Total number of subjects with adverse events and serious adverse events categorized by severity.",
                              "Total number of adverse events and serious adverse events categorized by relatedness to treatment defined by a medical professional.",
                              "Total number of subjects with adverse events categorized by relatedness to treatment by a medical professional"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants With Pre-Specified Infusion Associated Adverse Events",
                              "Number of Subjects With Serious Adverse Events by 31 Days After First Infusion",
                              "Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90",
                              "Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                              "Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity",
                              "Subjects With Adverse Events and Serious Adverse Events by Severity",
                              "Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment",
                              "Subjects With Adverse Events by Relatedness to Treatment"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Quantify safety of ARDOXSO\u2122, an interventional exosome therapy in COVID-19 in participants confirmed with SARS-CoV-2 infection who receive ARDOXSO\u2122 as an intervention.",
                              "Quantify efficacy of ARDOXSO\u2122, an interventional exosome therapy in COVID-19 in participants confirmed with SARS-CoV-2 infection who receive ARDOXSO\u2122 as an intervention."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO\u2122, perinatal MSC-derived exosome therapy.",
                              "Tabulate and report the number of IMV days for patients receiving ARDOXSO\u2122 perinatal MSC-derived exosome therapy."
                        ],
                        "NCTId": [
                              "NCT04798716"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [
                              "Danny F McAuley, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "OI is a physiological index of the severity of ARDS and measures both impaired oxygenation and the amount of mechanical ventilation delivered",
                              "Incidence of SAEs"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Oxygenation index (OI)",
                              "Incidence of Serious Adverse Events (SAEs)"
                        ],
                        "NCTId": [
                              "NCT03042143"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [
                              "Mike Royal, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "All-cause mortality rate at Day 28",
                              "Safety as assessed by incidence of AEs by type, frequency, severity, and causality using the Common Terminology Criteria for Adverse Events, Version 5 (CTCAEv5)",
                              "Safety as assessed by incidence of treatment-emergent AEs (TEAEs) by type, frequency, severity, and causality using CTCAEv5 criteria",
                              "Safety as assessed by incidence of serious AEs (SAEs) by type, frequency, severity, and causality using CTCAEv5 criteria",
                              "Safety as assessed by incidence of Infusion-related AEs (IrAEs) by type, frequency, severity, and causality using CTCAEv5 criteria over 4 hours"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "All-cause mortality rate at Day 28",
                              "Incidence of all adverse events (AEs) (safety)",
                              "Incidence of treatment-emergent adverse events (safety)",
                              "Incidence of severe adverse events (safety)",
                              "Incidence of infusion-related adverse events (safety)"
                        ],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [
                              "Sang Bum Hong, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Oxygen index at 3 days after mesenchymal stem cell infusion. Oxygen index is calculated as follows; ((FiO2) x (Mean airway pressure)) / (PaO2)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Oxygen index at 3 days after mesenchymal stem cell infusion"
                        ],
                        "NCTId": [
                              "NCT02112500"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 31, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety will be defined by the incidence of infusion-related adverse events as assessed by the treating physician",
                              "Safety will be defined by the incidence of TEAEs and TESAEs as assessed by the treating physician"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of infusion-related adverse events",
                              "Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)"
                        ],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "Peter Rosenberger, Prof."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "improvement of lung injury score (LIS), 0-16 points, severity increasing with higher points"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "lung injury score"
                        ],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [
                              "Antoni Torres, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of patients who died, by treatment group"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "All-cause mortality at day 28"
                        ],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Oxygenation index",
                              "Oxygenation index",
                              "Oxygenation index",
                              "Oxygenation index"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "PaO2/FiO2",
                              "PaO2/FiO2",
                              "PaO2/FiO2",
                              "PaO2/FiO2"
                        ],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Efficacy Endpoint; PaO2/FiO2 ratio"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio"
                        ],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of treatment-emergent serious adverse events (TE-SAEs) within 4 weeks after treatment, defined as one or more of the following untoward medical occurrences happening within the first 4 weeks after treatment.\n\ni. Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). ii. Event requiring inpatient hospitalization or prolongation of existing hospitalization (e.g., for worsening dyspnea).\n\niii. Event resulting in persistent or significant disability/incapacity. iv. Event resulting in death. v. Event leading to other clinically significant untoward laboratory test result(s) or medical condition(s), as determined by the Investigator.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months.",
                              "Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 months, this change in overall assessment will be the outcome in numbers of particants with a change.",
                              "Number of Participants with changes to Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 Months",
                              "Time to recovery of Sp02 to 90% or higher on room air (or the oxygen concentration the patient had before acute illness) after 10 minutes of spontaneous breathing.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in Blood Chemistry testing will be assessed at Baseline and 6 Months.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation testing will be assessed at Baseline and 6 Months.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent Serious Adverse Events",
                              "Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.",
                              "Number of Participants with Changes in Echocardiography Overall Assessment",
                              "Number of Participants with Changes to overall assessment of Electrocardiogram",
                              "Time to recovery of Sp02",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis"
                        ],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of product related adverse events through the duration of the study."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of product related adverse events through the duration of the study."
                        ],
                        "NCTId": [
                              "NCT05491681"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [
                              "Mike Royal, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "All-cause mortality rate at Day 28"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "All-cause mortality rate at Day 28"
                        ],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 25, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS."
                        ],
                        "NCTId": [
                              "NCT04524962"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [
                              "Mike Royal, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "All-cause mortality at Day 28"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Mortality at Day 28"
                        ],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety of UCMSCs will be reported as the percentage of participants in each treatment group that experienced a treatment related SAEs."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Percent of participants with treatment related Serious Adverse Events (SAE)"
                        ],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OverallOfficialName": [
                              "Ebru Kaya, MD",
                              "Gursel Turgut, Prof Dr",
                              "Ali Kocatas, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Chair",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Recovery of patient from mechanical and oxygen support",
                              "respiratory rates < 30 times /min",
                              "Oxygen saturation > 93% and pulmonary imaging of focus within 24-48 hours > 50% progression",
                              "arterial pressure of oxygen/the fraction of inspired oxygen>300mmHg"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change of clinical symptoms as respiratory distress or need for oxygen support",
                              "Change of cytokine storm parameters",
                              "Change of pulmonary functions",
                              "Change of clinical symptoms"
                        ],
                        "NCTId": [
                              "NCT04713878"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 39,
                        "OverallOfficialName": [
                              "Annetine C Gelijns, PhD",
                              "Michael Mack, MD",
                              "Peter Smith, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Director",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 14, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of all-cause mortality within 30 days of randomization."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of all-cause mortality"
                        ],
                        "NCTId": [
                              "NCT04371393"
                        ]
                  },
                  {
                        "Rank": 40,
                        "OverallOfficialName": [
                              "Peter Nemtinov, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Improvement of pulmonary function. Arterial oxygen tension PaO2 (in mmHg)/fractional inspired oxygen FiO2 (expressed as a fraction, not a percentage), most conveniently the P/F ratio. The normal P/F ratio is ~ 400-500 mmHg (~55-65 kPa). P/F ratio <300mmHg - sign of Acute Respiratory Distress Syndrome (ARDS)",
                              "Length of Hospital Stay",
                              "Marker for efficacy of treatment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.",
                              "Changes in length of hospital stay",
                              "Changes in mortality rate"
                        ],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 41,
                        "OverallOfficialName": [
                              "Antoine MONSEL, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 26, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group"
                        ],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 42,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Suspended"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 15, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)",
                              "Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate"
                        ],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 43,
                        "OverallOfficialName": [
                              "LaQuisa Hill, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Treatment-related serious adverse events (tSAE) will be considered as those directly related to the investigational infusion product per protocol defined criteria.",
                              "Change by at least two categories on a six category ordinal scale at day 14 post randomization per protocol defined criteria. The six-category ordinal scale ranges from 6 to 1 with a higher score indicates worse clinical outcome"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Treatment-related serious adverse events (tSAEs)",
                              "Change in clinical status at day 14"
                        ],
                        "NCTId": [
                              "NCT04345601"
                        ]
                  },
                  {
                        "Rank": 44,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 30, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of subjects with a DLT event during or within 24 hours after ULSC infusion\n\n[Dose Limiting Toxicities are treatment-emergent suspected adverse reactions graded as severe, such as severe infusion-related hypersensitivity toxicities of grade \u22653, and any treatment-emergent serious adverse event (SAE) will be investigated to determine if DLT.]",
                              "Number of subjects with a DLT event, suspected adverse reaction, or any serious adverse event (SAE) within 1 week of each ULSC infusion",
                              "Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study up to 1-month follow-up",
                              "Treatment-emergent adverse events (AE; incidence, grade, and assessment of relatedness or causality) and serious adverse events (SAE) during the study and up to the 12-month follow-up"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Dose Limiting Toxicity (DLT)",
                              "Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)",
                              "Treatment-emergent adverse events (AE) and serious adverse events (SAE)",
                              "Treatment-emergent adverse events (AE) and serious adverse events (SAE)"
                        ],
                        "NCTId": [
                              "NCT04494386"
                        ]
                  },
                  {
                        "Rank": 45,
                        "OverallOfficialName": [
                              "Jianming Tan Tan, M.D and Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Improvement of pulmonary function"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes of oxygenation index (PaO2/FiO2) ,blood gas test"
                        ],
                        "NCTId": [
                              "NCT04371601"
                        ]
                  },
                  {
                        "Rank": 46,
                        "OverallOfficialName": [
                              "Jolanta Airey, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Assessment of respiratory dysfunction"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups"
                        ],
                        "NCTId": [
                              "NCT04537351"
                        ]
                  },
                  {
                        "Rank": 47,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Complete remission"
                        ],
                        "NCTId": [
                              "NCT02985346"
                        ]
                  },
                  {
                        "Rank": 48,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 19, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To show how fetal blood transfusion (cord blood ) improve the outcome of COVID 19 patient ( mortality)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "\u2022 To evaluate the effect of increasing fetal hemoglobin protocol on the outcome in patients with fulminant COVID-19"
                        ],
                        "NCTId": [
                              "NCT05092724"
                        ]
                  },
                  {
                        "Rank": 49,
                        "OverallOfficialName": [
                              "Duncan J Stewart, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 22, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 to determine the maximum feasible tolerated dose (MFTD) of UC-MSCs given to patients with COVID-19"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0"
                        ],
                        "NCTId": [
                              "NCT04400032"
                        ]
                  },
                  {
                        "Rank": 50,
                        "OverallOfficialName": [
                              "Hugo G Oliveira, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 30, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Expressed as the total number of death due to all conditions during the clinical trial.",
                              "Number of participants with worsening of dyspnea as measured by the mMRC-Modified Medical Research Council (1 point increase in the measured scale). The mMRC Dyspnea Scale quantifies disability attributable to breathlessness (range from 1-4), and is useful for characterizing baseline dyspnea in patients with respiratory diseases.",
                              "Number of participants with respiratory functional worsening as measured by decrease of 15% or more in FEV1 (forced expiratory volume in one second). FEV1 is a measurement taken from a pulmonary function test. It calculates the amount of air that a person can force out of their lungs in 1 second.",
                              "Impairment of exercise capacity as measured by reduction of 35 m in the 6-minute walk test. The 6-min walk test (6 MWT) is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The test provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.",
                              "Outcome measure result: number of participants with 1 point increase in oxygen need as classification on the chart above 0 - no oxygen use 1- intermittent use <6h/day 2- intermittent use >6h/dia 3 - continuous oxygen use"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "All-cause death",
                              "Number of participants with worsening of dyspnea",
                              "Number of participants with respiratory functional worsening",
                              "Impairment of exercise capacity",
                              "Increased oxygen use"
                        ],
                        "NCTId": [
                              "NCT04018729"
                        ]
                  },
                  {
                        "Rank": 51,
                        "OverallOfficialName": [
                              "David Ingbar, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 25, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC"
                        ],
                        "NCTId": [
                              "NCT04466098"
                        ]
                  },
                  {
                        "Rank": 52,
                        "OverallOfficialName": [
                              "Itzhak Siev-Ner, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Frequency and severity of Adverse Events."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Frequency of Adverse Events"
                        ],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 53,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety assessment such as adverse events will be registered. Adverse events will be monitored during all trial",
                              "Safety assessments such as adverse events during the inhalation procedures will be registered."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with non-serious and serious adverse events during trial",
                              "Number of participants with non-serious and serious adverse during inhalation procedure"
                        ],
                        "NCTId": [
                              "NCT04602442"
                        ]
                  },
                  {
                        "Rank": 54,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "centr123@bk.ru"
                        ],
                        "PointOfContactOrganization": [
                              "MC Dinasty"
                        ],
                        "PointOfContactPhone": [
                              "+78462039808"
                        ],
                        "PointOfContactPhoneExt": [
                              "201"
                        ],
                        "PointOfContactTitle": [
                              "Tyumina Olga"
                        ],
                        "PrimaryCompletionDate": [
                              "October 1, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety assessment such as adverse events will be registered. Adverse events will be monitored during all trial",
                              "Safety assessments such as adverse events during the inhalation procedures will be registered."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants With Non-serious and Serious Adverse Events During Trial",
                              "Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure"
                        ],
                        "NCTId": [
                              "NCT04491240"
                        ]
                  },
                  {
                        "Rank": 55,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Withdrawn"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Changes in clinical critical treatment index"
                        ],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 56,
                        "OverallOfficialName": [
                              "Joanne Kurtzberg, MD",
                              "Lingye Chen, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 16, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of infusion reactions measured by any one of the following: fever, anaphlyaxis, rash, hypertension, hypotension, tachycardia, nausea, vomiting, or any other new or worsening symptoms associated with the infusion.",
                              "Incidence of later reactions attributed to the investigational product as measured by any one of the following: rash, infection, allergic reaction, or any other delayed symptoms associated with infusion of the investigational product.",
                              "Formation of new anti-HLA antibodies as measured by an antibody screen test at 28 days post first infusion of the investigational product."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of the Investigational Product- Infusion Reactions",
                              "Safety of the Investigational Product- delayed reactions",
                              "Safety of the Investigational Product- formation of anti-HLA antibodies"
                        ],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  }
            ]
      }
}